Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

Using 2% tofacitinib cream with narrowband ultraviolet B improved facial vitiligo by 70% in patients who didn't respond to previous treatments, with no side effects reported.

A man developed alopecia areata after starting cancer treatment with vandetanib.

An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.

The combination of encorafenib and binimetinib caused few skin issues.

Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.

Generic Palbociclib is safe and tolerable for treating certain breast cancer types.

Topical tacalcitol can treat psoriasis by acting directly on skin cells.

Posaconazole is a promising new treatment for toenail fungus.

Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

Baricitinib effectively treats severe alopecia for up to 104 weeks.

Tofacitinib might be used to treat hair loss.

TS-13 effectively stops tumor growth and reduces chemotherapy side effects.

Oral betamethasone works faster than oral tofacitinib for hair regrowth in alopecia areata.

Vemurafenib causes skin side effects similar to RASopathies, requiring regular skin checks and UVA protection.

Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.

Vorasidenib can cause unusual hair growth.

Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.

Tofacitinib helped a woman regrow hair with no major side effects.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.

A topical BRAF inhibitor, vemurafenib, can speed up wound healing and promote hair growth, especially in diabetic patients.

Baricitinib works better than methotrexate for severe alopecia areata.

Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.

A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.

Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.